IMAT - ultrafast tomography for coronary artery disease Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMAT - ultrafast tomography for coronary artery disease

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: David Winkler who wrote (2408)	4/16/1998 10:47:00 AM
From: Bruce Rozenblit	Read Replies (1) of 3725

This is great news but I have to throw a little water on the fire. The losses from HeartScan were responsible for 72% of last years loss. If it weren't for that and Asia didn't collapse in the fourth quarter, we might very well be in positive numbers now. What that means to us is a more stable share price over $5. Until that happens big institutional money will NOT come in and push the price up. This is a critical threshold for the stock. Imat will have to sell 10 machines this year to cover that loss and 6 more to make up for Seimens 5 million contribution. That's 16 that have to be sold just to cover those losses. They are going to need at least 50 million in revenue to break even and that's at least 30 machines. So, fully 1/3 of sales of a really good year are down the drain before we even get started. HeartScan is putting us on ice for another year. This is a very serious matter and is costing all of us a lot of money. There is a difference between bleeding and hemorrhaging and this is hemorrhaging.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next